Revolution Medicines (NASDAQ:RVMDW – Get Free Report) is projected to post its results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($2.0426) per share and revenue of $1.7730 million for the quarter.
Revolution Medicines Stock Performance
Shares of NASDAQ RVMDW traded down $0.63 during midday trading on Monday, reaching $8.93. 4,201 shares of the company were exchanged, compared to its average volume of 118,286. The stock’s 50-day moving average price is $7.86 and its 200-day moving average price is $4.67. Revolution Medicines has a one year low of $0.16 and a one year high of $10.12.
Revolution Medicines Company Profile
Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.
Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.
See Also
- Five stocks we like better than Revolution Medicines
- Large Caps Across Planes, Tech and Oil Announce Over $10 Billion in Buybacks
- A Sweet Beat and a Wearables Rally Came With Reasons to Pause
- 3 Healthcare Stocks With Fresh Dividend Hikes and Different Income Profiles
- 3 Humanoid Robot ETFs to Ride a Speculative Trend
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
